FDA Delays Effective Date for Spirulina Extract Color Additive

The FDA is delaying the effective date of its final order regarding the expanded use of spirulina extract as a color additive in human foods. This delay is in response to timely objections and a request for a hearing filed by Obelisk Tech Systems Inc. The agency will announce a new effective date or other administrative action later.

FDA Delays Effective Date for Spirulina Extract Color Additive

The FDA is delaying the effective date of its final order regarding the expanded use of spirulina extract as a color additive in human foods. This delay is due to timely objections and a request for a hearing filed by Obelisk Tech Systems Inc. The agency will publish a future document to announce a new effective date or other administrative action.

FDA Variance Approval Letter to Anthony Ritzko

The FDA's Center for Devices and Radiological Health (CDRH) has issued a variance approval letter to Anthony Ritzko. The letter, dated March 24, 2025, is available in both redacted and unredacted forms.

FDA Complaint Document

The Food and Drug Administration (FDA) has posted a complaint document related to its activities. This document is now closed for public comments. The FDA has provided a link to download the complaint document.

FDA Complaint Document

The FDA has posted a complaint document authored by CTP. The document was made available on March 24th and is now closed for public comments. No specific details about the complaint's content or the regulatory impact are provided.

FDA Complaint Document

The FDA has posted a complaint document related to its Center for Tobacco Products (CTP). The document was made available on March 24, 2026, and is open for public comment.

FDA Complaint Document

The FDA has posted a complaint document related to its regulatory activities. The document is available for download and further information can be accessed via the provided link. This notice serves to inform the public about the availability of this complaint.

FDA Complaint Document

The Food and Drug Administration (FDA) has posted a complaint document related to its activities. The document is available for review on the Regs.gov platform. No specific action is required from regulated entities at this time.

FDA Complaint Document Details

The FDA has posted a complaint document related to its activities, identified by docket number FDA-2026-H-2617-0001. The document is available for review on the Regulations.gov portal.

Cannabist Company Holdings Inc. - Material Definitive Agreement

The Cannabist Company Holdings Inc. has entered into an asset purchase agreement for the sale of its Delaware subsidiary's assets. The transaction is valued at $16.5 million, with a portion held in escrow for indemnification obligations. This filing reports the entry into this material definitive agreement.